Gut Inflammation Linked to Breast Cancer Reactivation
Researchers found that gut inflammation may trigger dormant breast cancer cells to begin dividing again within the bone marrow.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Should patients monitor systemic inflammation levels as a way to potentially lower their cancer relapse risk?
A study published in Cell Reports discovered that intestinal inflammation can reorganize bone marrow environments, potentially prompting dormant breast cancer cells to reactivate. This finding suggests a new potential connection between systemic inflammation and cancer recurrence.
Why it matters
Understanding how inflammatory processes reorganize the body's internal environments could eventually help clinicians identify high-risk periods for patients in remission. This development shifts focus toward managing systemic inflammation to prevent the reactivation of metastatic cells.
In a preclinical study published in Cell Reports, researchers used an artificial bone marrow model in mice to observe how intestinal colitis triggers cancer cell division. Scientists also confirmed that elevated levels of the HMGB2 molecule correlate with active tumor growth in human bone samples.
The players
Francis Crick Institute
A biomedical research center focused on understanding the fundamental biology of health and disease, including cancer metastasis.
The details
Researchers induced intestinal inflammation in mice to observe how systemic stress impacts dormant metastatic cells. This inflammation causes a reorganization of the bone marrow environment to support an increase in immune cell production. This process inadvertently releases HMGB2 molecules, which act as a signal that stimulates dormant cancer cells to break their inactivity and resume division.
Timeline
October 1, 2026: The study was published in the journal Cell Reports.
Health Landscape
This discovery from the Francis Crick Institute research program marks a shift in understanding metastatic dormancy by linking systemic immune signals to local tumor reactivation. It expands the scientific view of cancer recurrence beyond the primary site to include how the body's internal inflammatory state influences dormant cells.
For patients in remission, this research highlights the importance of discussing inflammation management, including infections or injuries, with a primary care physician or oncologist. It serves as a reminder to monitor and address systemic health issues that could potentially impact long-term recovery.
The takeaway
Systemic inflammation, such as that caused by gut issues, may serve as a biological switch for dormant breast cancer cells. Patients should maintain open communication with their oncology team regarding new health concerns, injuries, or persistent inflammatory conditions during remission.
Further reading
Learn more about the latest research on Cancer and its management.
More information
View the complete Cell Reports study on metastatic dormancy for further details.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Should patients monitor systemic inflammation levels as a way to potentially lower their cancer relapse risk?
